title: [Effects of allitridi capsules on endothelial function and clinical prognosis after percutaneous coronary intervention in coronary artery disease patients with diabetes mellitus].
abstract: OBJECTIVE
  To explore the effects of allitridi capsules on endothelial function and clinical prognosis after percutaneous coronary intervention (PCI) in coronary artery disease (CAD) patients with diabetes mellitus (DM).
  
  
  METHODS
  A total of 120 CAD patients with DM undergoing PCI were randomly assigned to receive conventional (control, n = 60) and additional allitridi treatment (120 mg/day, n = 60) for 3 months.Serum nitric oxide (NO) and intercellular adhesion molecule 1 (ICAM-1) levels were determined by enzyme-linked immunosorbent assay (ELISA) immediately and at 3 months post-PCI. Endothelial function was assessed by endothelium dependent flow-mediated dilation (FMD). Duration of follow-up was 1 year after PCI.
  
  
  RESULTS
  The clinical characteristics, serum NO and ICAM-1 levels and FMD at baseline were not different between two groups. At Month 3 post-PCI, serum NO level was markedly higher ((147 ± 32) vs (112 ± 24) µmol/L, P = 0.009) and serum ICAM-1 level was significantly lower ((182 ± 21) vs (232 ± 29) µmol/L, P = 0.021) in the allitridi group than in the control group.Furthermore, treatment of allitridi resulted in a significant improvement of FMD (8.2% ± 2.4% vs 6.4% ± 2.3%, P = 0.013). At Year 1 post-PCI, the incidence of major adverse cardiovascular event (MACE) was lower in the allitridi group than that in the control group (10.5% vs 17.2%, P = 0.022).
  
  
  CONCLUSIONS
  Allitridi capsules significantly improve the clinical prognosis after PCI in CAD patients with DM. Its mechanism may lies in improved endothelial function and vascular inflammatory state.
authors.affiliation: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Xiao-min
authors.initials: XM
authors.lastname: Nie
authors.forename: Ying-xin
authors.initials: YX
authors.lastname: Zhao
authors.forename: Dong-mei
authors.initials: DM
authors.lastname: Shi
authors.forename: Yu-yang
authors.initials: YY
authors.lastname: Liu
authors.forename: Zhi-ming
authors.initials: ZM
authors.lastname: Zhou
authors.forename: Li-xiao
authors.initials: LX
authors.lastname: Su
authors.forename: Yu-jie
authors.initials: YJ
authors.lastname: Zhou
mesh_terms: D000368:Aged; D000498:Allyl Compounds / Q000627:therapeutic use*; D002214:Capsules; D003324:Coronary Artery Disease / Q000378:metabolism* / Q000628:therapy; D003925:Diabetic Angiopathies / Q000378:metabolism* / Q000628:therapy; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood; D062645:Percutaneous Coronary Intervention; D011184:Postoperative Period; D013440:Sulfides / Q000627:therapeutic use*
chemical_list: D000498:Allyl Compounds; D002214:Capsules; D013440:Sulfides; C042577:diallyl trisulfide; D018799:Intercellular Adhesion Molecule-1; D009569:Nitric Oxide